CDC s Division of Diabetes Translation.

CDC ‘s Division of Diabetes Translation, works to reduce the preventable burden of diabetes through public health leadership, partnership, research, programs and measures to implement the science into practice.

The municipalities in the Beacon Community Program contained in Brewer, Maine, Spokane, Washington, Grand Junction, Colorado, New Orleans, Louisiana, Stoneville, Mississippi, Cincinnati, Ohio, Tulsa, Oklahoma, Hawaii, Buffalo, New York, Salt Lake City, Utah, Indianapolis, Indiana, Danville, Pennsylvania, Providence, Rhode Iceland, San Diego, California, Detroit, Michigan, Rochester, Minnesota, and Concord, North Carolina.Neuralstem.. This news release may contain forward-looking statements for purposes of the ‘safe harbor’provisions of Private Securities Litigation Act of 1995. Investors are advised that these forward-looking statements in this news release about potential applications to Neuralstem technology constitute forward-looking statements that involve risks and uncertainties, including, include, without limitation, the uncertainties risk in the development and marketing of potential product, clinical study results of and regulatory approval or releases, Capital Cities capital, depending must employees and maintaining our intellectual property rights.

– Cautionary Statement Regarding Forward – Looking Send.. Neuronal integrate the humanity stem cell at nervous out of the ALS of ALS.

On NeuralstemNeuralstem patented technology it possible, the first time in the ability to neural stem of the human brain and spinal cord professional amounts, and the capability to intervene control differentiation of these cells, physiologically producing related human neurons and glial Important diseases affecting the central nervous systems of the Company the Company by of research goal the currently ongoing ischemic Spastic Paraplegia ischemic Paraplegia, Traumatic Spinal cord injuries, Huntington’s disease and amyotrophic lateral . The company submitted an IND application with the FDA of THAN clinical trials in December 2008 and has become an collaboration agreement with the Albert-Ludwigs University of Freiburg, Germany for for clinical trials Huntington disease development of entered.